BCYC

Bicycle Therapeutics Ltd (BCYC) is an innovative clinical-stage biopharmaceutical company headquartered in Cambridge, UK, specializing in the development of novel therapeutics utilizing its proprietary bicyclic peptide platform. Targeting significant unmet medical needs across various disease areas, particularly in oncology, Bicycle aims to revolutionize treatment modalities with its distinct approach to drug design. The company boasts a robust pipeline of candidates, underscoring its commitment to advancing therapeutic solutions that could redefine standard care for patients facing complex health challenges. As it progresses through clinical trials, Bicycle Therapeutics is well-positioned to make a substantial impact in the biopharmaceutical landscape.